Head and neck cancer

#BioNTech #Head and neck cancer #Immunotherapy #mRNA #Phase III trial

BioNTech’s mRNA immunotherapy fails to meet primary endpoint

BioNTech has announced the first topline results from the AHEAD-MERIT Phase II/III clinical trial for its investigational mRNA cancer immunotherapy BNT113 (tenumomeran/raplemomeran or tenu-ra).  The clinical trial is evaluating BNT113 in combination with pembrolizumab compared to pembrolizumab monotherapy as a first-line treatment for patients with unresectable recurrent… Read More

#Cancer Research #News

Head and neck cancer
#Head and neck cancer #Oncology #Phase II trial #QBiotics

Phase II data show durable responses in head and neck cancer

QBiotics has announced positive results from its Phase II QB46C-H08 trial, with tigilanol tiglate achieving a 78% Objective Response Rate (ORR) in patients with head and neck solid malignancies who were refractory to standard of care.   The company says the result, based on 14 responses across 18… Read More

#Cancer Research #News

#Cancer vaccine #Head and neck cancer #NEC Corporation #Oncology #Phase I trial #Transgene

100% three-year disease-free survival in head and neck cancer

Transgene and NEC Corporation have reported sustained 100% three-year disease-free survival (DFS) in patients treated with TG4050 in the Phase I part of a randomised Phase I/II trial.   TG4050 is the first individualised neoantigen therapeutic vaccine (INTV) based on the myvac platform.  It is… Read More

#Cancer Research #Editor's Choice #News

#AI #Cancer research #Cervical cancer #Clinical trial #Colorectal cancer #Genetics / genomics #Head and neck cancer #MHRA #Obesity #Pistoia Alliance #Precision medicine #University College London #University of Cambridge #Weight loss

DDW Highlights: 9 June 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a cancer drug demonstrated it could reduce tumours by as much as… Read More

#Podcasts

#AI #Cancer research #Cervical cancer #Clinical trial #Colorectal cancer #Genetics / genomics #Head and neck cancer #MHRA #Obesity #Pistoia Alliance #Precision medicine #University College London #University of Cambridge #Weight loss

This week in Drug Discovery (1 June – 5 June) 

News round-up for 1 June – 5 June by Bruno Quinney, Content Team at DDW.  This week, a cancer drug has demonstrated it could reduce tumours by as much as 55%. Elsewhere, AI has been a recurrent theme in both clinical trials and drug development.   The top stories:… Read More

#News

Tumour microenvironment
#Cancer research #Cervical cancer #Colorectal cancer #Head and neck cancer

Drug could reduce tumours by 55%, results show 

An experimental drug could shrink tumours by up to 55%, results show.  GRWD5769, developed by biotech company Greywolf Therapeutics, is a first-in-class oral small molecule inhibitor of Endoplasmic Reticulum Aminopeptidase 1 (ERAP1), an enzyme that regulates tumour antigen presentation on MHC-I.  The drug works by… Read More

#Cancer Research #News

Scan to diagnose head and neck cancer
#Cancer research #Head and neck cancer #HPV #Protein targets #Ubiquitin-proteasome

What impact could protein stabilisation have for cancer patients?

The latest episode of the DDW ‘In Conversation With’ series is available to listen to below. This week, Bruno Quinney speaks to Anthony Johnson and Matthew Fyfe from Outrun Therapeutics. Outrun is a biotech specialising in protein stabilisation, an approach being applied to treat HPV+ head and… Read More

#Cancer Research #Featured Podcasts #Podcasts

#Biotech #Cancer research #Head and neck cancer

Outrun to develop treatment for head and neck cancer 

Biotechnology company Outrun Therapeutics has announced its lead programme for the treatment of HPV positive head and neck cancer.  The company has selected an E6AP inhibitor strategy as the lead programme from its first-in-class therapeutic pipeline, developed through its proprietary XL discovery platform. The platform has been… Read More

#Cancer Research #News

#Antibody drug conjugate (ADC) #Head and neck cancer #Oncology #Phase I trial #Pyxis Oncology

First-in-concept ADC shows promise in head and neck cancer

Pyxis Oncology has announced positive preliminary data from its ongoing Phase I clinical studies evaluating micvotabart pelidotin (MICVO) in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).   MICVO is an antibody-drug conjugate (ADC) targeting extradomain-B of fibronectin (EDB+FN), a non-cellular structural component of the… Read More

#Cancer Research #News

Bispecific antibodies
#Bispecific Antibodies #Genmab #Head and neck cancer #Mergers and acquisitions #Oncology

Genmab to acquire Merus for approximately $8 billion

Genmab has agreed to acquire Merus, a clinical-stage biotechnology company with a late-stage breakthrough therapy asset called petosemtamab, which is in Phase III development.  Genmab will pay $97.00 per share in an all-cash transaction representing a transaction value of approximately $8 billion.   The proposed acquisition of Merus is expected to… Read More

#Business & Investment #News

Blushwood tree
#Head and neck cancer #Oncology #Plant-based #QBiotics #Solid tumours #The Institute of Cancer Research

Could a molecule from a rainforest tree treat solid tumour cancers?

Scientists at The Institute of Cancer Research, London, are collaborating with life sciences company QBiotics to understand the molecular and cellular mechanisms of a potential new cancer drug.  The collaborative team will study the effects of tigilanol tiglate – a naturally occurring small molecule derived from the… Read More

#Cancer Research #Editor's Choice #News

Scan to diagnose head and neck cancer
#Cancer vaccine #Head and neck cancer #Oncology #Phase II trial #Scancell Holdings

Vaccine achieves early clinical validation in head and neck cancer

The combination of Scancell’s Modi-1 and a checkpoint blockade has shown promise in HPV negative head and neck squamous cell carcinoma (SCCHN) in an ongoing Phase IIa study.  The Phase IIa dose expansion ModiFY study is evaluating the safety, tolerability, and preliminary efficacy of Modi-1 in combination… Read More

#Cancer Research #News

Salivary glands
#Avacta #Head and neck cancer #Oncology #Peptide-drug conjugate #Phase I trial

Avacta’s peptide drug conjugate shrinks tumours in salivary gland cancer

Avacta has announced positive early efficacy data for its peptide drug conjugate, AVA6000, demonstrating clinically meaningful tumour shrinkage in patients with salivary gland cancer (SGC).  AVA6000 consists of doxorubicin chemotherapy conjugated with Avacta’s pre|CISION peptide, specifically cleaved by fibroblast activation protein-alpha (FAP) in the tumour microenvironment. Read More

#Cancer Research #Editor's Choice #News

CAR-T therapy
#Biosyngen #CAR-T #Cell therapy #FDA #Head and neck cancer #Oncology #Solid tumours

CAR-T therapy for nasopharyngeal cancer enters Phase II trials

The US Food and Drug Administration (FDA) has approved a Phase II clinical trial for Biosyngen’s BRG01, an EBV-specific CAR-T cell therapy. This marks the first cell therapy to enter Phase lI trials in both the US and China for the treatment of relapsed/metastatic EBV-positive nasopharyngeal carcinoma. The Center for… Read More

#News #Regulatory

Fusobacterium
#Bacteria #Guy’s and St Thomas' #Head and neck cancer #King's College London #Oncology

Bacteria destroys head and neck cancer tumours

Researchers at Guy’s and St Thomas’, and King’s College London in the UK have found that a bacteria is toxic for head and neck cancer and could lead to better treatments for patients. Fusobacterium is usually associated with the progression of bowel cancer. However, new research… Read More

#Cancer Research #Editor's Choice #News

#Blood brain barrier #Calliditas Therapeutics #Cancer #Cancer research #Clinical trials #Drug discovery #Head and neck cancer #Immunotherapy #Neuroscience #Oncology #Plant-based #Schizophrenia #Smoking cessation #Squamous cell carcinoma #Vaping

New DDW Highlights episode: 8 May 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  A leading news story this week has been the announcement of positive Phase II… Read More

#News